A phase I study of farletuzumab, a humanized anti-folate receptor α monoclonal antibody, in patients with solid tumors

A phase I study of farletuzumab, a humanized anti-folate receptor α monoclonal antibody, in patients with solid tumors

Farletuzumab is a humanized monoclonal antibody against folate receptor α (FRA). The purpose of the study is to assess safety and tolerability, the pharmacokinetic (PK) profile, and preliminary antitumor effect. Patients with ovarian cancer (OC) or FRA-expressing solid tumors who are resistant to st...

Full description

Bibliographic Details
Main Authors: Sasaki, Yasutsuna, Miwa, Keisuke, Yamashita, Keishi, Sunakawa, Yu, Shimada, Ken, Ishida, Hiroo, Hasegawa, Kosei, Fujiwara, Keiichi, Kodaira, Makoto, Fujiwara, Yasuhiro, Namiki, Masayuki, Matsuda, Minami, Takeuchi, Yutaka, Katsumata, Noriyuki
Format: Online
Language:English
Published: Springer US 2014
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4387250/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4387250/

Similar Items